A single dose for children, adolescents, and adults—robust results with statistical weight
In the long struggle against dengue fever — a disease that claimed more than 970 Brazilian lives in 2022 alone — the Instituto Butantan has offered a measured but meaningful answer: a single-dose vaccine showing 79.6% overall efficacy across 16,200 volunteers in 14 Brazilian states. The result, still preliminary and awaiting a five-year conclusion in 2024, suggests that a country long burdened by the disease may be approaching the threshold of its own protection. What makes this moment notable is not only the science, but the sovereignty it implies — Brazil producing, at scale, a shield against one of its most persistent afflictions.
- Dengue killed over 970 Brazilians in 2022, and with no approved domestic vaccine, the disease has continued to extract a toll that researchers have spent years trying to interrupt.
- Preliminary trial data — 100 dengue cases among the unvaccinated versus just 35 among the vaccinated — delivered a statistically significant result that energized the Butantan team and moved the science closer to regulatory review.
- Protection is uneven across the virus's four serotypes and prior infection histories, with efficacy ranging from 69.6% against type 2 to 89.5% against type 1, leaving questions about types 3 and 4 still open.
- Safety data came back clean — no hospitalizations, no deaths, and serious adverse events in fewer than 0.1% of volunteers — though the absence of severe cases means that particular protection remains unmeasured for now.
- With ANVISA approval still pending and final five-year data not due until 2024, Butantan is already planning three filling lines capable of producing 50 million doses annually, positioning Brazil as a potential supplier to dengue-affected nations worldwide.
In mid-December, the Instituto Butantan announced that its dengue vaccine had shown 79.6% effectiveness in preliminary phase 3 trial results — a finding drawn from two years of monitoring 16,200 volunteers spread across 16 research centers in 14 Brazilian states. Of the 135 dengue cases recorded during the study window, 100 occurred in the unvaccinated group and just 35 among those who received the shot. Medical director Fernanda Boulos described the result as robust and statistically significant, noting that the vaccine required only a single dose and could eventually be administered across age groups. Full results won't arrive until 2024, when the five-year follow-up concludes.
Protection varied depending on prior exposure: volunteers who had already encountered dengue showed 89.2% efficacy, while first-time infections yielded 73.5%. By serotype, type 1 reached 89.5% and type 2 came in at 69.6%; data for types 3 and 4 remained unavailable because those strains hadn't circulated widely enough during the trial period. Lead virologist Maurício Nogueira suggested types 3 and 4 would likely perform closer to type 1, based on the biological behavior of the virus.
Safety results were reassuring. No hospitalizations or deaths occurred across the entire cohort, and serious adverse events affected fewer than 0.1% of participants. Side effects were broadly comparable between vaccinated and placebo groups, with the expected exceptions of fever and localized skin irritation appearing more often in vaccinated volunteers.
The vaccine's antigens were originally licensed through the U.S. National Institutes of Health; Butantan partnered with MSD in 2018 and holds exclusive rights to manufacture and sell the product within Brazil, pending ANVISA approval. Executive director Dimas Covas framed the achievement as evidence of Brazilian scientific capacity — and pointed to the year's death toll of over 970 as the moral weight behind the effort. Manufacturing director Daniella Cristina Ventini Monteiro confirmed the institute could produce up to 50 million doses annually once regulatory clearance is granted, with three filling lines ready to meet domestic public health demand.
The Instituto Butantan announced preliminary results from its dengue vaccine trial in mid-December, revealing 79.6% effectiveness across its study population. The finding emerged from two years of monitoring 16,200 volunteers enrolled in the final phase of testing before regulatory approval—a moment that energized the research team, though the full picture won't arrive until 2024, when the five-year follow-up concludes.
The trial itself was distributed across 16 research centers in 14 Brazilian states. Researchers randomly assigned participants into two groups: two-thirds received the vaccine, one-third got placebo. Over the two-year window, 135 dengue cases appeared among the volunteers. The split was stark: 100 cases among the unvaccinated group, 35 among those who received the shot. Fernanda Boulos, the institute's medical director, called it a robust result with statistical significance, and emphasized that the vaccine required only a single dose and could eventually be given to children, adolescents, and adults alike. The data would move toward publication in a scientific journal the following year.
The protection varied depending on a person's prior exposure to dengue. Among volunteers who had been infected before entering the study, the vaccine showed 89.2% effectiveness. For those encountering the virus for the first time, protection dropped to 73.5%—still substantial, but noticeably lower. When researchers broke down results by the four dengue serotypes, the picture became more granular. Type 1 showed 89.5% efficacy. Type 2 lagged at 69.6%. No data yet existed for types 3 and 4, simply because those strains hadn't circulated widely enough in Brazil during the study window to generate meaningful numbers. Maurício Nogueira, a virologist at the medical school in São José do Rio Preto and one of the trial's lead researchers, suggested that types 3 and 4 would likely perform closer to type 1 based on what scientists understand about how the virus behaves biologically.
Safety data looked clean. No hospitalizations or deaths occurred in either group across the entire volunteer cohort. This meant researchers couldn't yet measure how well the vaccine protected against severe dengue—but they reasoned that such strong protection against symptomatic infection probably signaled equally strong protection against the worst outcomes. Among the 16,200 volunteers, only three people—less than 0.1%—experienced serious adverse events. The institute reported that side effects were comparable between the vaccinated and placebo groups, with the expected exceptions: fever and skin irritation at sites away from the injection point appeared more often in the vaccinated group, as anticipated.
The vaccine itself descended from antigens licensed through the U.S. National Institutes of Health. In 2018, Butantan had partnered with pharmaceutical company MSD, which held the global license outside Brazil. Within Brazil, Butantan retained exclusive rights to manufacture and sell the product, pending approval from the country's health regulator, ANVISA. Dimas Covas, the institute's executive director, framed the work as proof of Brazilian capacity: the country could produce not just for itself but for any nation struggling with dengue. He invoked the year's toll—more than 970 deaths from the disease in Brazil alone—as moral weight behind the effort.
Production capacity was already being planned. Daniella Cristina Ventini Monteiro, who manages manufacturing at Butantan, said the institute could produce up to 50 million doses annually once the vaccine cleared regulatory hurdles. The facility could deploy three separate filling lines to meet domestic public health demand. The vaccine itself used a weakened form of the virus—a proven approach in immunology. The path forward hinged on ANVISA's decision, but the preliminary numbers had given the team reason to believe they were close to something that could reshape Brazil's relationship with a disease that had killed nearly a thousand people in a single year.
Citações Notáveis
Although preliminary, it is a robust result with statistical significance. And still of a vaccine in single dose that could be indicated for children, adolescents and adults. We are optimistic.— Fernanda Boulos, medical director of Butantan Institute
Having a vaccine developed and manufactured entirely here at Butantan reinforces one of our purposes: to show that Brazil has productive capacity to serve not only our territory, but any other country suffering from dengue.— Dimas Covas, executive director of Butantan Foundation
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this is a single-dose vaccine, when other dengue vaccines require multiple shots?
Because compliance drops sharply with each additional dose. A single shot means fewer people abandon the series halfway through, and it's far easier to roll out in public health campaigns, especially in rural areas where follow-up appointments are hard to schedule.
The efficacy is 79.6% overall, but only 69.6% against serotype 2. That's a meaningful gap. Should people worry about that?
It's lower, yes, but 69.6% still prevents roughly seven out of ten infections with that strain. The real concern is that serotype 2 is the one that tends to cause the most severe disease, so researchers are watching that number closely as more data comes in.
Why don't they have efficacy data for serotypes 3 and 4 yet?
Those strains simply weren't circulating widely in Brazil during the study period. You can't measure protection against a virus that isn't present. The researchers expect those numbers will look better once they appear, but it's an honest gap in the data right now.
Only three serious adverse events out of 16,200 people. That's extraordinarily safe. Is that normal for vaccines?
It's genuinely rare to see adverse event rates that low. Most vaccines have higher rates. This one appears to be very well-tolerated, which is important because you need public confidence to vaccinate hundreds of millions of people.
The article mentions 970 deaths from dengue in Brazil in 2022. How does a vaccine prevent that?
It doesn't prevent all of it—no vaccine is 100% effective. But if you vaccinate enough people, you break transmission chains. Fewer infections mean fewer severe cases, fewer hospitalizations, fewer deaths. At scale, even 79.6% efficacy saves lives.
What happens if ANVISA says no?
The vaccine doesn't reach the Brazilian market, at least not immediately. But the data is solid enough that other countries might pursue it, or Butantan could reapply with the full five-year data in 2024. Regulatory rejection isn't the end—it's usually a request for more information.